HT
AMRX icon

Headlands Technologies’s Amneal Pharmaceuticals AMRX Stock Holding History

Headlands Technologies’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,478
Closed -$255K – 714
2026
Q1 		$255K Sell
20,478
-41,247
-67% -$554K 0.03% 542
2025
Q4 		$778K Buy
61,725
+21,357
+53% +$244K 0.06% 311
2025
Q3 		$404K Buy
40,368
+15,676
+63% +$141K 0.03% 407
2025
Q2 		$200K Buy
24,692
+21,007
+570% +$158K 0.02% 469
2025
Q1 		$30.9K Buy
+3,685
New +$30.8K ﹤0.01% 791

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Headlands Technologies's AMRX Position: Q2 2026 in Review

Headlands Technologies sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 20,478 shares — an estimated $255K sold.

Headlands Technologies first reported a position in AMRX in Q1 2025 and held it in 5 quarters. The position peaked at $778K in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Headlands Technologies reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 20,478 Amneal Pharmaceuticals shares in Q2 2026, an estimated $255K.
  • Headlands Technologies first reported a position in Amneal Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Headlands Technologies's Amneal Pharmaceuticals position peaked at $778K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.